Genmab A/S, founded in February 1999 by Florian Schönharting and Lisa Drakeman, is a Danish biotechnology company headquartered in Copenhagen, Denmark. The company operates internationally with subsidiaries in the Netherlands, USA, and Japan. Genmab's core mission is to improve the lives of patients through innovative antibody therapeutics. The company focuses on developing and commercializing differentiated antibody products for the treatment of cancer and other serious diseases, leveraging its proprietary antibody technologies.
Notable figures affiliated with Genmab include its founders and key investors from BankInvest Biomedical venture fund. Genmab has achieved significant milestones, including dual listings on the Copenhagen Stock Exchange and NASDAQ Global Select Market. The company has made substantial impacts in the biotech industry, particularly with its successful development and commercialization of therapeutic antibodies. Its contributions have advanced cancer treatment options and improved patient outcomes globally.
